GlassScriptPhysician profile
Susan Lotkowski
NPI 1992738470
$6,060.80
in general payments reported to CMS, 2019-2025
67 companies · $542 in 2025
The $542 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $893 · 2021: $1,474 · 2022: $1,246 · 2023: $689 · 2024: $648 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $871.62 | 2020-2025 | |
| Biogen, INC. | $298.41 | 2019-2025 | Vumerity, Spinraza, Tysabri |
| Allergan, INC. | $278.30 | 2020-2022 | |
| Ucb, INC. | $265.89 | 2019-2025 | Rystiggo, Zilbrysq, Fintepla |
| Teva Pharmaceuticals USA, INC. | $246.97 | 2019-2025 | Austedo Xr, Austedo Xr |
| Eisai INC. | $217.71 | 2019-2025 | |
| Lilly USA, LLC | $196.86 | 2019-2025 | Amyvid, Kisunla |
| Kyowa Kirin, INC. | $193.01 | 2020-2024 | Nourianz |
| Amgen INC. | $158.41 | 2019-2025 | Uplizna |
| Supernus Pharmaceuticals, INC. | $150.90 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $144.98 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $144.47 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Emd Serono, INC. | $139.61 | 2020-2022 | |
| Impel Pharmaceuticals INC. | $134.58 | 2023 | Trudhesa |
| Avanir Pharmaceuticals, INC. | $123.70 | 2019-2021 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Lotkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.